Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
Provided By PR Newswire
Last update: Aug 14, 2024
— Improved loss from operations by 81% —
— Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections —
Read more at prnewswire.comNASDAQ:ADTX (11/25/2025, 1:52:58 PM)
2.77
-0.8 (-22.41%)
Find more stocks in the Stock Screener
ADTX Latest News and Analysis
